$15M Series Seed — AlphaRose Therapeutics

We imagine a different world for children born with severe autism, epilepsy, or neurodevelopmental delays. Our technology has shown to fix the underlying cause of these types of genetic diseases, and often reverse damage done by genetic mutations that cause these terrible outcomes. Children talking for the first time, no more seizures, swimming when they could barely walk. This is why AlphaRose exists.

AlphaRose finished an oversubscribed round with notable commitments from Labcorp and Suncoast Ventures. With over $5M raised, AlphaRose is now raising a $15M round to take Rosiphersen into clinical trials and validate their RINAE platform by getting human data.

Highlights:

Rosiphersen shows a 10x safety window in vivo ($700M in potential peak annual revenue)
RINAE AI platform showed best in class performance, with a 70% target hit rate
SOT Caller epigenetic platform is showing positive data in human cells for upregulation
Robust pipeline of similar neuro genetic treatments ($2.5B in potential peak annual revenue)

AlphaRose is poised to turn a 240B market, into over $1T with platform approval from regulators.